Evotec moves business back to UK


German drug discovery company Evotec will close its operations in Thane, India, and move them back to its Abingdon, UK, facility. The move will cost up to €4 million (£3.4 million), and the company’s 120 employees in India will lose their jobs. The firm said it is responding to its European customers’ increasing requirements to operate nearby.

Mario Polywka, Evotec’s chief operating officer, said that the company was due to move its Indian chemistry operations in June 2014. However, ' because of growing customer requirements for European-based activities, we came to the conclusion to exit our operations in India completely’.

Evotec moved into India in 2007, aiming to supply low-cost compound libraries to the pharmaceutical industry. But Polywka was adamant that moving projects back to the UK is a positive step for the company. ‘Through this realignment we will be able to most efficiently serve our customers, utilise our UK chemistry resources… and also realise cost savings.’


Related Content

Business roundup

29 September 2011 Business

news image

Industry news, October 2011

Reaching out

22 May 2014 Premium contentFeature

news image

Andy Extance surveys how pharma uses outsourcing in a variety of different ways

Most Read

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Chemists zinc up ‘aromatic’ metal cubes

2 March 2015 Research

news image

Metal-organic clusters share electrons between eight covalently linked metal atoms

Most Commented

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Hepatitis C drug patent challenged in Europe

19 February 2015 Business

news image

Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent